journal
MENU ▼
Read by QxMD icon Read
search

Journal of Hepatocellular Carcinoma

journal
https://www.readbyqxmd.com/read/30123783/hepatitis-c-virus-associated-hepatocellular-carcinoma-as-a-second-primary-malignancy-exposing-an-overlooked-presentation-of-liver-cancer
#1
Dima Dandachi, Manal Hassan, Ahmed Kaseb, Georgios Angelidakis, Harrys A Torres
Introduction: Chronic hepatitis C virus (HCV) infection is one of the leading causes of hepatocellular carcinoma (HCC) worldwide. Antiviral therapy in patients with HCV infection reduces the risk of primary HCC development by 71%-75%. HCV-infected patients with different primary cancers are also at risk for HCC development as a second primary malignancy (HCC-SPM). Limited information is available on the occurrence and characteristics of HCC-SPM. Herein, we determine the prevalence and clinical features of HCV-associated HCC-SPM when compared to primary HCC...
2018: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/30050880/hepatocellular-cancer-pain-impact-and-management-challenges
#2
REVIEW
Nathaniel Christian-Miller, Catherine Frenette
Hepatocellular carcinoma (HCC) remains the most common primary liver malignancy. Pain comprises one of the most pervasive and troubling symptoms of HCC and may have severely negative effects on patient's quality of life. Furthermore, because HCC frequently arises in the setting of cirrhosis, treating pain related to this malignancy poses a clinical challenge. This article summarizes manifestations of hepatocellular cancer pain, common obstacles to treatment, and practical HCC pain management.
2018: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/29984212/role-of-wnt-%C3%AE-catenin-signaling-in-hepatocellular-carcinoma-pathogenesis-and-clinical-significance
#3
REVIEW
Ahmed M Khalaf, David Fuentes, Ali I Morshid, Mata R Burke, Ahmed O Kaseb, Manal Hassan, John D Hazle, Khaled M Elsayes
Hepatocellular carcinoma (HCC) is one of the most common primary hepatic malignancies and one of the fastest-growing causes of cancer-related mortality in the United States. The molecular basis of HCC carcinogenesis has not been clearly identified. Among the molecular signaling pathways implicated in the pathogenesis of HCC, the Wnt/β-catenin signaling pathway is one of the most frequently activated. A great effort is under way to clearly understand the role of this pathway in the pathogenesis of HCC and its role in the transition from chronic liver diseases, including viral hepatitis, to hepatocellular adenomas (HCAs) and HCCs and its targetability in novel therapies...
2018: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/29911076/decreased-hepatocellular-carcinoma-tumor-burden-with-the-achievement-of-hepatitis-c-virus-sustained-virologic-response-unlocking-the-potential-of-t-cell-mediated-immunosurveillance
#4
Anna S Griffith, Paul H Hayashi, Lauren Mb Burke, Autumn J McRee
We describe two cases of patients with hepatitis C virus (HCV) treated with direct-acting antiviral (DAA) therapy who had dramatic improvement in hepatocellular carcinoma (HCC) tumor burden with DAA therapy alone. Both patients were diagnosed with HCC on screening magnetic resonance imaging shortly after beginning DAA therapy. Both patients achieved sustained virologic response (SVR) with dramatic improvement in HCC tumor burden on follow-up imaging without HCC treatment. Patients with multifocal or advanced HCC are infrequently treated with antiviral therapy for HCV...
2018: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/29774205/editorial-charting-the-future-of-hepatocellular-carcinoma-publications
#5
EDITORIAL
Ahmed Omar Kaseb
No abstract text is available yet for this article.
2018: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/29520343/efficacy-of-loco-regional-treatment-for-hepatocellular-carcinoma-prior-to-living-donor-liver-transplantation-a-report-from-a-single-center-in-egypt
#6
Mohammad Kamal Shaker, Iman F Montasser, Mohamed Sakr, Mohamed Elgharib, Hany M Dabbous, Hend Ebada, Ahmed El Dorry, Mohamed Bahaa, Mahmoud El Meteini
Background and aim: The number of loco-regional therapies (LRTs) for hepatocellular carcinoma (HCC) has increased dramatically during the past decade, bridging or downstaging patients on the waiting list for liver transplantation. This study aimed to analyze the outcomes of LRTs prior to living donor liver transplantation in patients with HCC. Methods: Sixty-two HCC patients received living donor liver transplantation at Ain Shams Center for Organ Transplantation over a 2-year period...
2018: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/29404284/pretreatment-neutrophil-lymphocyte-ratio-useful-prognostic-biomarker-in-hepatocellular-carcinoma
#7
REVIEW
Marc Najjar, Surbhi Agrawal, Jean C Emond, Karim J Halazun
Hepatocellular carcinoma (HCC) is the most common liver malignancy and the third most common cause of cancer-related deaths. Liver resection (LR) and liver transplantation (LT) are the only curative modalities for HCC. Despite recent advances and the adoption of the Milan and University of California, San Francisco, criteria, HCC recurrence after LR and LT remains a challenge. Several markers and prognostic scores have been proposed to predict tumor aggressiveness and supplement radiological data; among them, neutrophil-lymphocyte ratio (NLR) has recently gained significant interest...
2018: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/29392123/phase-ii-trial-of-som230-pasireotide-lar-in-patients-with-unresectable-hepatocellular-carcinoma
#8
Lynn G Feun, Medhi Wangpaichitr, Ying-Ying Li, Deukwoo Kwon, Stephen P Richman, Peter J Hosein, Niramol Savaraj
Background: A phase II trial of pasireotide was performed to assess its efficacy and safety in advanced or metastatic hepatocellular carcinoma (HCC). Patients and methods: Patients with advanced HCC and Child-Pugh score ≤7 received pasireotide LAR 60 mg intramuscularly every 28 days. Primary endpoint was disease control rate. Secondary endpoints were time to tumor progression, response rate, treatment-related adverse events, and overall survival. Serum insulin growth factor-1 was measured before and after pasireotide...
2018: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/29392122/liver-resection-versus-radiofrequency-ablation-for-hepatitis-b-virus-related-small-hepatocellular-carcinoma
#9
Bin Liang, Siyang Yao, Jiapeng Zhou, Zongkui Li, Tianqi Liu
Background: To compare the outcomes of liver resection (LR) with radiofrequency ablation (RFA) for patients with hepatitis B virus (HBV)-related small hepatocellular carcinoma (HCC). Methods: A total of 122 HBV-related small HCC patients who underwent LR (n=64) or RFA (n=58) were involved in this retrospective study. Their basic clinical data, postoperative complications, survival outcomes, and prognostic factors were compared and analyzed. Results: Patients in the LR group had more serious complications (11 versus 0) and longer postoperative hospital stays (11...
2018: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/29692983/basic-mri-for-the-liver-oncologists-and-surgeons
#10
REVIEW
Lan N Vu, John N Morelli, Janio Szklaruk
Magnetic resonance imaging (MRI) is the modality of choice for liver imaging due to its superior contrast resolution in comparison with computer tomography and the ability to provide both morphologic and physiologic information. The physics of MR are complex, and a detailed understanding is not required to appreciate findings on an MRI exam. Here, we attempt to introduce the basic principles of MRI with respect to hepatic imaging focusing on various commonly encountered hepatic diseases. The purpose is to facilitate an appreciation of the various diagnostic capabilities of MR among hepatic oncologists and surgeons and to foster an understanding of when MR studies may be appropriate in the care of their patients...
2017: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/29238703/characterization-of-alpha-fetoprotein-effects-on-dendritic-cell-and-its-function-as-effector-immune-response-activator
#11
Jeremiah Suryatenggara, Heri Wibowo, Wahyuni Lukita Atmodjo, George Mathew
Tumor antigen alpha-fetoprotein (AFP) can promote immune tolerance toward tumor cells by inducing regulatory functions of the immune system. The purpose of this study was to characterize the effects of AFP on dendritic cells (DC) in their antitumor immune response stimulation and subsequent immune tolerance toward tumor cells. Monocytes were cultured in medium with GM-CSF and IL-4 and incubated for 6 days to generate immature DC (imDC). AFP was added into the treatment group at the beginning of the monocyte-derived DC culture...
2017: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/29184856/optimal-therapy-for-patients-with-hepatocellular-carcinoma-and-resistance-or-intolerance-to-sorafenib-challenges-and-solutions
#12
REVIEW
Emily M Ray, Hanna K Sanoff
The only US Food and Drug Administration (FDA)-approved first-line systemic therapy for hepatocellular carcinoma (HCC) is sorafenib; however, resistance or intolerance to sorafenib is unfortunately common. In this review, we briefly describe systemic therapies that can be considered for patients with HCC who show resistance or intolerance to sorafenib. For all patients with HCC who need systemic therapy, we strongly advocate for participation in clinical trials. Cytotoxic chemotherapy plays a minor role in the treatment of advanced HCC, with some data supporting the use of FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) and GEMOX (gemcitabine-oxaliplatin)...
2017: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/29082223/healthcare-costs-of-transarterial-chemoembolization-in-the-treatment-of-hepatocellular-carcinoma
#13
Waleed Fateen, Farooq Khan, Richard J O'Neill, Martin W James, Stephen D Ryder, Guruprasad P Aithal
BACKGROUND: A meta-analysis comparing drug-eluting beads transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (cTACE) has recently been published. On balance, no significant differences were found in terms of objective response and overall survival. The impact on healthcare costs had been studied in small series based on a hypothetical model and was in favor of DEB-TACE. We aimed to evaluate and compare health-care costs and effectiveness of both modalities in a cohort of patients from Nottingham, UK...
2017: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/28848723/a-phase-i-trial-using-local-regional-treatment-nonlethal-irradiation-intratumoral-and-systemic-polyinosinic-polycytidylic-acid-polylysine-carboxymethylcellulose-to-treat-liver-cancer-in-search-of-the-abscopal-effect
#14
Andrew N de la Torre, Sohail Contractor, Ismael Castaneda, Charles S Cathcart, Dolly Razdan, David Klyde, Piotr Kisza, Sharon F Gonzales, Andres M Salazar
PURPOSE: To determine the safety of an approach to immunologically enhance local treatment of hepatocellular cancer (HCC) by combining nonlethal radiation, local regional therapy with intratumoral injection, and systemic administration of a potent Toll-like receptor (TLR) immune adjuvant. METHODS: Patients with HCC not eligible for liver transplant or surgery were subject to: 1) 3 fractions of 2-Gy focal nonlethal radiation to increase tumor antigen expression, 2) intra-/peri-tumoral (IT) injection of the TLR3 agonist, polyinosinic-polycytidylic acid polylysine carboxymethylcellulose (poly-ICLC), to induce an immunologic "danger" response in the tumor microenvironment with local regional therapy, and 3) systemic boosting of immunity with intramuscular poly-ICLC...
2017: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/28795053/transarterial-chemoembolization-for-the-treatment-of-hepatocellular-carcinoma-a-review
#15
REVIEW
Rodolfo Sacco, Gherardo Tapete, Natalia Simonetti, Rossella Sellitri, Veronica Natali, Sara Melissari, Giuseppe Cabibbo, Lilia Biscaglia, Giampaolo Bresci, Luca Giacomelli
According to the current European Association for the Study of Liver guidelines, transarterial chemoembolization (TACE) is the recommended first-line therapy for patients with intermediate-stage (Barcelona Clinic Liver Cancer-B class) hepatocellular carcinoma (HCC). The efficacy of this therapy is supported by robust evidence; however, there is still a lack of standardization in treatment methodology, and TACE protocols are widely variable. Moreover, TACE can be associated with a number of contraindications...
2017: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/28721349/hepatocellular-carcinoma-early-stage-management-challenges
#16
REVIEW
Derek J Erstad, Kenneth K Tanabe
Hepatocellular carcinoma (HCC) is a major cause of cancer death and is increasing in incidence. This review focuses on HCC surveillance and treatment of early-stage disease, which are essential to improving outcomes. Multiple societies have published HCC surveillance guidelines, but screening efforts have been limited by noncompliance and overall lack of testing for patients with undiagnosed chronic liver disease. Treatment of early-stage HCC has become increasingly complex due to expanding therapeutic options and better outcomes with established treatments...
2017: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/28553624/screening-for-hepatocellular-carcinoma-patient-selection-and-perspectives
#17
REVIEW
Waleed Fateen, Stephen D Ryder
Hepatocellular carcinoma (HCC) develops on the background of liver cirrhosis often from multiple, simultaneous factors. The diagnosis of a single small HCC comes with good prognosis and provides a potential for cure. In contrast, the diagnosis of multifocal, large HCC has high mortality and poor prognosis. Unfortunately, the majority of HCC is diagnosed at such late stages. A surveillance program endorsed by regional liver societies involves six-monthly ultrasound surveillance of at-risk patients. This had been in action for the last two decades...
2017: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/28443252/open-label-phase-ii-clinical-trial-in-75-patients-with-advanced-hepatocellular-carcinoma-receiving-daily-dose-of-tableted-liver-cancer-vaccine-hepcortespenlisimut-l
#18
Marina G Tarakanovskaya, Jigjidsuren Chinburen, Purev Batchuluun, Chogsom Munkhzaya, Genden Purevsuren, Dorjiin Dandii, Tsogkhuu Hulan, Dandii Oyungerel, Galyna A Kutsyna, Alan A Reid, Vika Borisova, Allen I Bain, Vichai Jirathitikal, Aldar S Bourinbaiar
BACKGROUND: An increasing number of studies is now devoted to immunotherapy of cancer. We evaluated the clinical benefit of hepcortespenlisimut-L (Hepko-V5 [formerly known as V5])-an oral therapeutic vaccine designated by the United States Food and Drug Administration (FDA) as an orphan drug for treatment of hepatocellular carcinoma (HCC). V5 was initially developed by us in 2002 to treat hepatitis B or C viral infections and liver cirrhosis. METHODS: The outcome of open-label Phase II trial of daily dose of V5 pill was analyzed retrospectively...
2017: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/28331845/irreversible-electroporation-of-hepatocellular-carcinoma-patient-selection-and-perspectives
#19
REVIEW
Asha Zimmerman, David Grand, Kevin P Charpentier
Irreversible electroporation (IRE) is a novel form of tissue ablation that uses high-current electrical pulses to induce pore formation of the cell lipid bilayer, leading to cell death. The safety of IRE for ablation of hepatocellular carcinoma (HCC) has been established. Outcome data for ablation of HCC by IRE are limited, but early results are encouraging and suggest equivalency to the outcomes obtained for thermal ablation for appropriately selected, small (<3 cm) tumors. Long-term oncologic efficacy and histopathologic response data have not been published, and therefore, application of IRE for the treatment of HCC should still be viewed with caution...
2017: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/28331844/a-single-institution-report-of-19-hepatocellular-carcinoma-patients-with-bile-duct-tumor-thrombus
#20
Anon Chotirosniramit, Akkaphod Liwattanakun, Worakitti Lapisatepun, Wasana Ko-Iam, Trichak Sandhu, Sunhawit Junrungsee
BACKGROUND: Obstructive jaundice caused due to bile duct tumor thrombus (BDTT) in a hepatocellular carcinoma (HCC) patient is an uncommon event. This study reports our clinical experiences and evaluates the outcomes of HCC patients with BDTT in a single institution. METHODS: A retrospective review of 19 HCC patients with secondary obstructive jaundice caused due to BDTT during a 15-year period was conducted. RESULTS: At the time of diagnosis, 14 (73...
2017: Journal of Hepatocellular Carcinoma
journal
journal
53528
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"